(BMRN) Biomarin Pharmaceutical - Ratings and Ratios
Enzyme Replacement, Growth Injection, Metabolic Enzyme, Gene Therapy
BMRN EPS (Earnings per Share)
BMRN Revenue
Description: BMRN Biomarin Pharmaceutical July 22, 2025
BioMarin Pharmaceutical Inc. is a biotechnology company that develops and commercializes therapies for rare and life-threatening diseases. The companys product portfolio includes several enzyme replacement therapies and other treatments for conditions such as mucopolysaccharidosis, achondroplasia, and phenylketonuria.
From a business perspective, BioMarins products are sold to specialty pharmacies, hospitals, and pharmaceutical wholesalers, both domestically and internationally. The company has also entered into license and collaboration agreements with other pharmaceutical companies, such as Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A.
To evaluate BioMarins performance, we can look at key performance indicators (KPIs) such as revenue growth, product sales, and research and development (R&D) expenses. With a market capitalization of approximately $10.99 billion, BioMarins revenue is likely driven by the sales of its marketed products, including VIMIZIM, VOXZOGO, NAGLAZYME, and PALYNZIQ. The companys R&D pipeline is also robust, with several products in development, including BMN333, BMN349, and BMN351.
From a financial perspective, BioMarins price-to-earnings (P/E) ratio is around 21.22, indicating that the stock may be moderately valued compared to its earnings. The forward P/E ratio is lower, at 13.57, suggesting that analysts expect earnings to grow in the future. The companys return on equity (RoE) is around 9.46%, which is a reasonable return considering the industrys capital requirements.
To further analyze BioMarins stock, we can examine its trading metrics. The stocks current price is around $57.29, with a 20-day simple moving average (SMA) of $56.69 and a 50-day SMA of $57.38. The stocks 200-day SMA is $63.98, indicating a potential long-term downtrend. The average true range (ATR) is around 1.51, or 2.64%, indicating moderate volatility.
BMRN Stock Overview
| Market Cap in USD | 10,461m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1999-07-23 |
BMRN Stock Ratings
| Growth Rating | -62.3% |
| Fundamental | 83.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -36.3% |
| Analyst Rating | 4.34 of 5 |
BMRN Dividends
Currently no dividends paidBMRN Growth Ratios
| Growth Correlation 3m | -83.1% |
| Growth Correlation 12m | -81.7% |
| Growth Correlation 5y | -31% |
| CAGR 5y | -14.96% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.27 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.49 |
| Sharpe Ratio 12m | 0.18 |
| Alpha | -33.44 |
| Beta | 0.330 |
| Volatility | 32.38% |
| Current Volume | 6453k |
| Average Volume 20d | 2211.9k |
| Stop Loss | 51.7 (-3.3%) |
| Signal | 0.66 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (657.2m TTM) > 0 and > 6% of Revenue (6% = 183.8m TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 6.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 101.9% (prev 84.70%; Δ 17.18pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 766.8m > Net Income 657.2m (YES >=105%, WARN >=100%) |
| Net Debt (-610.0m) to EBITDA (895.2m) ratio: -0.68 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (196.6m) change vs 12m ago -1.93% (target <= -2.0% for YES) |
| Gross Margin 79.56% (prev 79.46%; Δ 0.09pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.19% (prev 36.63%; Δ 5.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 76.25 (EBITDA TTM 895.2m / Interest Expense TTM 11.1m) >= 6 (WARN >= 3) |
Altman Z'' 3.77
| (A) 0.42 = (Total Current Assets 3.81b - Total Current Liabilities 684.2m) / Total Assets 7.46b |
| (B) 0.03 = Retained Earnings (Balance) 231.5m / Total Assets 7.46b |
| (C) 0.12 = EBIT TTM 845.4m / Avg Total Assets 7.26b |
| (D) 0.13 = Book Value of Equity 187.2m / Total Liabilities 1.43b |
| Total Rating: 3.77 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.68
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 7.18% = 3.59 |
| 3. FCF Margin 22.57% = 5.64 |
| 4. Debt/Equity 0.10 = 2.50 |
| 5. Debt/Ebitda -0.68 = 2.50 |
| 6. ROIC - WACC (= 3.95)% = 4.94 |
| 7. RoE 11.48% = 0.96 |
| 8. Rev. Trend 97.71% = 7.33 |
| 9. EPS Trend 94.58% = 4.73 |
What is the price of BMRN shares?
Over the past week, the price has changed by -0.59%, over one month by -0.98%, over three months by -8.00% and over the past year by -23.73%.
Is Biomarin Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMRN is around 45.01 USD . This means that BMRN is currently overvalued and has a potential downside of -15.85%.
Is BMRN a buy, sell or hold?
- Strong Buy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BMRN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 94.8 | 77.2% |
| Analysts Target Price | 94.8 | 77.2% |
| ValueRay Target Price | 49.4 | -7.6% |
BMRN Fundamental Data Overview October 28, 2025
P/E Trailing = 16.0708
P/E Forward = 10.8342
P/S = 3.4146
P/B = 1.7704
P/EG = 0.6335
Beta = 0.33
Revenue TTM = 3.06b USD
EBIT TTM = 845.4m USD
EBITDA TTM = 895.2m USD
Long Term Debt = 596.2m USD (from longTermDebt, last quarter)
Short Term Debt = 7.70m USD (from shortTermDebt, last quarter)
Debt = 603.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -610.0m USD (from netDebt column, last quarter)
Enterprise Value = 9.63b USD (10.46b + Debt 603.9m - CCE 1.43b)
Interest Coverage Ratio = 76.25 (Ebit TTM 845.4m / Interest Expense TTM 11.1m)
FCF Yield = 7.18% (FCF TTM 691.4m / Enterprise Value 9.63b)
FCF Margin = 22.57% (FCF TTM 691.4m / Revenue TTM 3.06b)
Net Margin = 21.45% (Net Income TTM 657.2m / Revenue TTM 3.06b)
Gross Margin = 79.56% ((Revenue TTM 3.06b - Cost of Revenue TTM 626.2m) / Revenue TTM)
Gross Margin QoQ = 81.82% (prev 79.66%)
Tobins Q-Ratio = 1.29 (Enterprise Value 9.63b / Total Assets 7.46b)
Interest Expense / Debt = 0.44% (Interest Expense 2.68m / Debt 603.9m)
Taxrate = 19.25% (57.3m / 297.9m)
NOPAT = 682.7m (EBIT 845.4m * (1 - 19.25%))
Current Ratio = 5.56 (Total Current Assets 3.81b / Total Current Liabilities 684.2m)
Debt / Equity = 0.10 (Debt 603.9m / totalStockholderEquity, last quarter 6.03b)
Debt / EBITDA = -0.68 (Net Debt -610.0m / EBITDA 895.2m)
Debt / FCF = -0.88 (Net Debt -610.0m / FCF TTM 691.4m)
Total Stockholder Equity = 5.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.81% (Net Income 657.2m / Total Assets 7.46b)
RoE = 11.48% (Net Income TTM 657.2m / Total Stockholder Equity 5.72b)
RoCE = 13.38% (EBIT 845.4m / Capital Employed (Equity 5.72b + L.T.Debt 596.2m))
RoIC = 10.80% (NOPAT 682.7m / Invested Capital 6.32b)
WACC = 6.85% (E(10.46b)/V(11.06b) * Re(7.23%) + D(603.9m)/V(11.06b) * Rd(0.44%) * (1-Tc(0.19)))
Discount Rate = 7.23% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 1.24%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈500.0m ; Y1≈616.8m ; Y5≈1.05b
Fair Price DCF = 93.22 (DCF Value 17.90b / Shares Outstanding 192.0m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 94.58 | EPS CAGR: 284.1% | SUE: 3.61 | # QB: 3
Revenue Correlation: 97.71 | Revenue CAGR: 19.53% | SUE: 2.34 | # QB: 1
Additional Sources for BMRN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle